Drug Trial Radar · NCT07354503
Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis
Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Jun 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- The Children's Hospital of Zhejiang University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 21, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To further evaluate the efficacy and safety of Telitacicept in the treatment of pediatric IgA vasculitis nephritis (IgAVN) within real-world settings, this study employs a multicenter, retrospective and prospective observational research design. It aims to compare the efficacy of Telitacicept with that of glucocorticoids, thereby providing clinicians with a reference for the rational and standardized application of Telitacicept.
Conditions
- IgAVN
- IgA Vasculitis
Interventions
Collect clinical data from the patients.Device
This study exclusively prospectively collected clinical data from the patients and did not involve any therapeutic interventions.
This study exclusively prospectively collected clinical data from the patients and did not involve any therapeutic interventionsDrug
This study exclusively prospectively collected clinical data from the patients and did not involve any therapeutic interventions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete remission rate of urinary protein [Efficacy]Time frame: From enrollment to the 48th week after treatment
- The rate of change in urinary protein [Efficacy]Time frame: From enrollment to the 48th week after treatment
- The rate of change in urinary protein [Efficacy]Time frame: From enrollment to the 48th week after treatment.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.